MARKET

EARS

EARS

Auris Medical Holding Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.050
-0.190
-5.86%
After Hours: 3.010 -0.04 -1.31% 17:03 02/26 EST
OPEN
3.120
PREV CLOSE
3.240
HIGH
3.400
LOW
2.920
VOLUME
634.95K
TURNOVER
--
52 WEEK HIGH
6.60
52 WEEK LOW
0.6500
MARKET CAP
40.19M
P/E (TTM)
-2.4016
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Best Penny Stocks To Buy Now? 5 Tech Stocks To Watch For February
Feb 24, 2021 (Penny Stocks via COMTEX) -- Tech Penny Stocks Continue Gaining Momentum In February As February gets rolling, there is a variety of potentially...
Penny Stocks · 2d ago
Vertigo Drugs Market Research Development, Top Companies, Trends And Growth 2018 To 2028
Feb 24, 2021 (Heraldkeepers) -- Global vertigo drugs market is segregated on the basis of product as, antihistamines, phenothiazines, and benzodiazepines....
Heraldkeepers · 2d ago
Vaccinex, Evolus leads healthcare gainers; China SXT Pharmaceuticals, Motus GI among major losers
Gainers: Vaccinex VCNX +148%, Evolus EOLS +60%, TransEnterix (TRXC) +17%, BioVie (BIVI) +16%, Auris Medical (EARS) +13%.Losers: China SXT Pharmaceuticals SXTC -21%, Motus GI MOTS -16%, 180 Life Sciences ATNF -11%, Lucira Health (LHDX) -10%, Onconova Therap...
Seekingalpha · 02/19 15:59
Surgical Robots Market Size, Trends, Demand & Competitive Analysis 2020-2025
Feb 18, 2021 (SUPER MARKET RESEARCH via COMTEX) -- According to IMARC Group's latest report, titled "Surgical Robots Market: Global Industry Trends, Share,...
SUPER MARKET RESEARCH · 02/18 06:41
Vertigo Drugs Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Feb 15, 2021 (Market Insight Reports) -- The report for Vertigo Drugs offers an assiduous analysis of contemporary market trends, driving factors, consumer...
Market Insight Reports · 02/15 13:56
Vertigo Drugs Market Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2025
Feb 10, 2021 (Heraldkeepers) -- Market Research Engine has published a new report titled as "Cosmetic Skin Care Market Size, By Product (Moisturizers,...
Heraldkeepers · 02/10 07:47
Vertigo Drugs Market Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025
Jan 30, 2021 (Heraldkeepers) -- The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview...
Heraldkeepers · 01/30 07:52
Auris Medical announces initiation of clinical investigation of AM-301 in allergic rhinitis
Auris Medical (EARS) with its affiliate Altamira Medica AG announces the initiation of a clinical investigation of AM-301, a drug-free nasal spray, in allergic rhinitis.The clinical investigation is an open-label randomized cross-over study
Seekingalpha · 01/29 13:46
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EARS. Analyze the recent business situations of Auris Medical Holding Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EARS stock price target is 15.27 with a high estimate of 15.27 and a low estimate of 15.27.
EPS
Institutional Holdings
Institutions: 21
Institutional Holdings: 1.12M
% Owned: 8.51%
Shares Outstanding: 13.18M
TypeInstitutionsShares
Increased
1
1.55K
New
10
146.54K
Decreased
1
76
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Chief Executive Officer/Director
Thomas Meyer
Non-Executive Vice Chairman
James Healy
Chief Financial Officer/Primary Contact
Hernan Levett
General Counsel
Anne Zoller
Other/IR Contact Officer
Cindy McGee
Other
Andrea Braun
Other
Thomas Jung
Other
Bettina Stubinski
Director
Mats Blom
Non-Executive Independent Director
Oliver Kubli
Director
Alain Munoz
Non-Executive Independent Director
Berndt Modig
Non-Executive Independent Director
Armando Anido
Non-Executive Independent Director
Calvin Roberts
Non-Executive Independent Director
Wolfgang Arnold
  • Dividends
  • Splits
  • Insider Activity
No Data
About EARS
Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.

Webull offers kinds of Auris Medical Holding Ltd stock information, including NASDAQ:EARS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EARS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EARS stock methods without spending real money on the virtual paper trading platform.